CME Courses 1-5
9 a.m.-4 p.m.
CME Courses 6-11
10 a.m.-5 p.m.
Registration/Course Enrollment Open
APA Resource Center Open
11 a.m.-5 p.m.
Publishers’ Bookfair Open
1 p.m.-5 p.m.
CME Courses 12-16
7 p.m.-10 p.m.
Industry-Supported Symposia
IS1. Psychiatry Practice Paradigm: The Emerging Role of the Psychiatrist in Treating Alzheimer’s Disease Supported by Eisai Inc., Pfizer Inc.
A. Mild Cognitive Impairment Versus Early Alzheimer’s Disease J. Michael Ryan, M.D.
B. Mild to Moderate Alzheimer’s Disease Pierre N. Tariot, M.D.
C. Depression in Alzheimer’s Disease William E. Reichman, M.D.
D. Dementia With Abnormal Neurological Features J. Michael Ryan, M.D.
E. Severe Dementia With Agitation and Nursing Home Issues William E. Reichman, M.D.
F. Psychosis in Alzheimer’s Disease William E. Reichman, M.D.
G. Practice Management Gary S. Moak, M.D.
IS2. Molecules and Mood Disorders: Drug Discovery and the Treatment of Depression Supported by Forest Laboratories Inc.
A. Antidepressant Drug Discovery: The Ways, Means, and Needs Michael J. Owens, Ph.D.
B. The Phenomenon of Single-Isomer Drugs Joseph Gal, Ph.D.
C. Refining Current Therapies: Clinical Implications for the Treatment of Depression C. Lindsay DeVane, Pharm.D.
D. The State-of-the-Art in Treating Depression: 2002 Andrew A. Nierenberg, M.D.
IS3. Bipolar Disorder: New Nationwide Data on Misdiagnosis and Community Costs Supported by GlaxoSmithKline
A. Prevalence and Burden of Depression in the Community and Primary Care Myrna M. Weissman, Ph.D.
B. The True Prevalence of Bipolar Spectrum Disorder Robert M.A. Hirschfeld, M.D.
C. Human Suffering and Economic Burden in a Large Community Joseph R. Calabrese, M.D.
D. New Developments in the Treatment of Bipolar Disorder Mark A. Frye, M.D.
E. The Challenge of Bipolar Disorder in Children and Adolescents Karen D. Wagner, M.D.
IS4. Improving Patient Outcomes Across the Spectrum of Bipolar Disorder Supported by Pfizer Inc.
A. Managing the Pendulum of Mood in Bipolar Disorder Jack M. Gorman, M.D.
B. Acute Mania: Pharmacologic Treatment Strategies David J. Kupfer, M.D.
C. Phase-Specific Psychotherapy for Bipolar Disorder Holly A. Swartz, M.D.
D. Gender and Bipolar Disorder: Future Directions Ellen Leibenluft, M.D.
E. The Longitudinal Course of Bipolar Disorder Across the Life Cycle Ellen Frank, Ph.D.
IS5. New Approaches for Treating ADHD: The Whole-Life Perspective Supported by Eli Lilly and Company
A. ADHD: DSM-IV and Beyond Thomas E. Brown, Ph.D.
B. ADHD: Phenotypes and Pathophysiologies Albert J. Allen, M.D.
C. New ADHD Treatment Options on the Horizon Christopher J. Kratochvil, M.D.
D. From Childhood to Adolescence: Diagnosis and Comorbidity Issues Thomas J. Spencer, M.D.
E. Issues in Diagnosing and Treating the Adult ADHD Patient Lenard A. Adler, M.D.
IS6. Antipsychotic Therapy and Cardiovascular Disease: The Unfolding Story Supported by Janssen Pharmaceutica
A. Antipsychotic Therapy in Patients With Comorbidities: Issues and Polypharmacy Donald C. Goff, M.D.
B. Torsade de Pointes, QT, and Antipsychotic Drugs Walter V. Vieweg, M.D.
C. A Focus on Health: Consequences of Long-Term Antipsychotic Therapy Donna A. Wirshing, M.D.
D. Antipsychotics and Diabetes: A Current Perspective on Epidemiology Michael J. Sernyak, M.D.
E. Mechanisms of Antipsychotic-Induced Glucose Dysregulation and Insulin Resistance John W. Newcomer, M.D. ▪
